Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Thoracic malignancies 1

1703 - Comprehensive Genomic Profiling (CGP) of Thymic Gland Carcinomas (536O)

Date

17 Nov 2017

Session

Thoracic malignancies 1

Presenters

James Creeden

Citation

Annals of Oncology (2017) 28 (suppl_10): x166-x168. 10.1093/annonc/mdx677

Authors

J. Creeden1, J. Ross2, P. Vanden Borre3, N. Almog4, A. Schrock4, J. Chung4, J. Vergilio2, J. Suh5, S. Ramkissoon2, S. Ali4, V. Miller6, P. Stephens7, J. Elvin2, L. Gay2

Author affiliations

  • 1 Roche Fmi Asia Pacificroche Fmi Asia Pacific, Shanghai Roche Pharmaceuticals China, 201203 - Shanghai/CN
  • 2 Pathology, Foundation Medicine, Inc., 02142 - Cambridge/US
  • 3 Biomedical Informatics, Foundation Medicine, Inc., 02142 - Cambridge/US
  • 4 Clinical Development, Foundation Medicine, Inc., 02142 - Cambridge/US
  • 5 Pathology, Foundation Medicine, Inc., 27560 - Morrisville/US
  • 6 Medical Affairs, Foundation Medicine, Inc., 02142 - Cambridge/US
  • 7 Cancer Genomics, Foundation Medicine, Inc., 02142 - Cambridge/US
More

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 1703

Background

Thymic gland carcinomas include a variety of histologic subtypes with variable clinical aggressiveness and response to local and systemic therapies. We queried whether CGP could refine tumor subtypes and uncover new targeted and immunotherapy options for patients with relapsed and metastatic disease (mTC).

Methods

FFPE sections of 174 consecutive cases of mTC was sequenced using hybridization-captured, adaptor ligation-based libraries to a mean coverage depth of > 500X for up to 315 cancer-related genes plus 37 introns from 28 genes frequently rearranged in cancer. Total mutational burden (TMB) was determined on 1.1 Mb. Clinically relevant genomic alterations (CRGA) were defined as GA linked to drugs on the market or under evaluation in mechanism driven clinical trials.

Results

All mTC were clinically advanced and included 4% adenocarcinomas (TAC), 3% basaloid (TBC), 3% lymphoepitheliomatous (TLEC), 17% neuroendocrine (TNEC), 31% non-NE undifferentiated (TNOS), 40% squamous and 2% sarcomatoid (TSRC) carcinomas (Table). mTC were twice as common in men than women, had a peak incidence in late middle age, and featured an average of 4 GA/case and 0.9 CRGA/case. The most common molecular targets were KIT and PIK3CA. Other targets were PDGFRA, FGFR3, PTCH1, FBXW7, BRCA2, IDH1, ERBB2 and ERBB3. The more frequent subtypes (TNEC, TSCC and TNOS) tended to have more GA, with KIT targets in ∼ 10% of cases. Low TMB in mTC was common; only 6% of cases had >10 mut/Mb and 3% had >20 mut/Mb. Examples of mTC with responses to targeted therapies will be presented.

Conclusions

mTC histologic subtypes have varying GA and TMB status. The more common TSCC, TNEC and TNOS feature more GA, and when combined with TAC have more CRGA including KIT mutations and higher TMB. CGP shows promise to guide both targeted and immunotherapy selection for patients with this rare malignancy.

Clinical trial identification

Legal entity responsible for the study

Foundation Medicine, Inc.

Funding

None

Disclosure

J. Creeden: Employee of Roche, J. Ross, P. Vanden Borre, N. Almog, A. Schrock, J. Chung, J-A. Vergilio, J. Suh, S. Ramkissoon, S. Ali, V. Miller, P. Stephens, J. Elvin, L. Gay: Foundation Medicine (employment, equity)Table: 536O

TACTBCTLECTNECTNOSTSCCTSRC
Patients7553054694
Median Age (y)48585048575761
Gender43% F60% F20% F37% F24% F34% F50%F
GA/tumor4.02.81.03.34.14.14.8
CRGA0.90.300.90.81.01.0
Significant GAPDGFRA FGFR3 KIT MET PTCH1CDKN2A FBXW7CDKN2A MEN1KIT BRCA2 IDH1 ERBB2 ERBB3KIT PTEN PIK3CAKIT FGFR3 PIK3CAERBB2 IDH1 KIT
TMB >10 mut/Mb14%0%0%3%5%9%0%
TMB >20 mut/Mb0%0%0%3%5%9%0%

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.